Zacks Investment Management
CBIO icon

Zacks Investment Management’s Crescent Biopharma CBIO Stock Holding History

Zacks Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-170
Closed -$64K – 532
2020
Q4 		$64K Hold
170
– – ﹤0.01% 511
2020
Q3 		$52K Hold
170
– – ﹤0.01% 493
2020
Q2 		$64K Hold
170
– – ﹤0.01% 494
2020
Q1 		$39K Sell
170
-599
-78% -$229K ﹤0.01% 484
2019
Q4 		$407K Buy
+769
New +$416K 0.01% 465

Other funds holding CBIO

BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's CBIO Position: Q1 2021 in Review

Zacks Investment Management sold out of Crescent Biopharma (CBIO) in Q1 2021, closing a stake of 170 shares — an estimated $64K sold.

Zacks Investment Management first reported a position in CBIO in Q4 2019 and held it in 5 quarters. The position peaked at $407K in Q4 2019. 78 funds tracked by Wall St. Rank hold CBIO as of Q1 2021.

  • Zacks Investment Management reported no remaining Crescent Biopharma position as of Q1 2021 after selling out during the quarter.
  • Zacks Investment Management sold 170 Crescent Biopharma shares in Q1 2021, an estimated $64K.
  • Zacks Investment Management first reported a position in Crescent Biopharma in Q4 2019 and held it in 5 quarters.
  • Zacks Investment Management's Crescent Biopharma position peaked at $407K in Q4 2019.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2021.

Based on Zacks Investment Management's 13F filing for Q1 2021, filed 17 May 2021.